Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.

The treatment of pancreatic carcinoma remains one of the most formidable challenges in oncology. Curative resection, currently the only available treatment option, provides no significant impact on long-term survival. The recent development of multimodal treatment options for pancreatic cancer has provided clinical benefits and improved patient survival. In this study, we retrospectively evaluated our experiences with multimodal therapy, including radiotherapy and chemotherapy with gemcitabine, for the treatment of resectable pancreatic cancer. Fifty-eight patients with ordinary pancreatic carcinoma who underwent surgical resection at Kochi Medical School were studied. The clinical and pathological factors and multimodal treatment for pancreatic carcinoma that influenced patient survival were analyzed. Cumulative 1-, 3- and 5-year survival rates after surgery for ordinary pancreatic carcinoma were 62.2, 20.3 and 20.3%, respectively. The overall 4-year survival rate of patients subjected to adjuvant chemotherapy with gemcitabine after curative resection for ordinary pancreatic carcinoma is 39.1%. Adjuvant chemotherapy with gemcitabine provided a significantly better prognosis for patients following curative surgical resection than curative surgical resection alone (P=0.035). Although the rate of survival was greater for patients who underwent radiotherapy than those who did not, the difference was not statistically significant (P=0.054). Postoperative local recurrence around the nerve plexus of celiac and superior mesenteric arteries was better controlled in patients who underwent radiotherapy than those who did not. Adjuvant chemotherapy with gemcitabine after curative resection provides a significant survival benefit for patients with pancreatic carcinoma. Our results suggest that the postoperative recurrence of ordinary pancreatic carcinoma will be reduced by multimodal treatment using radiotherapy and adjuvant chemotherapy with gemcitabine.

[1]  H. Friess,et al.  Surgical treatment of pancreatic cancer: the role of adjuvant and multimodal therapies. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  S. Kondo,et al.  Distal Pancreatectomy With En Bloc Celiac Axis Resection for Locally Advanced Pancreatic Body Cancer: Long-term Results , 2007, Annals of surgery.

[3]  D. Stocken,et al.  A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin , 2007, Annals of Surgical Oncology.

[4]  T. Kamigaki,et al.  Impact of Gemcitabine on the Survival of Patients With Stage IV Pancreatic Cancer , 2007, Pancreas.

[5]  W. Hohenberger,et al.  Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO , 2007, BMC Cancer.

[6]  T. Kinoshitá,et al.  Clinical results of extended lymphadenectomy and intraoperative radiotherapy for pancreatic adenocarcinoma. , 2007, Hepato-gastroenterology.

[7]  H. Friess,et al.  Systematic review and meta‐analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer , 2007, The British journal of surgery.

[8]  T. Fujii,et al.  Oncological problems in pancreatic cancer surgery. , 2006, World journal of gastroenterology.

[9]  W. Sause,et al.  Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinoma. , 2005, International journal of radiation oncology, biology, physics.

[10]  D. Sargent,et al.  A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. , 2005, Surgery.

[11]  P. van Houtte,et al.  Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study. , 2005, International journal of radiation oncology, biology, physics.

[12]  K. Mizumoto,et al.  ERT following IORT improves survival of patients with resectable pancreatic cancer. , 2005, Hepato-gastroenterology.

[13]  R. Andersson,et al.  Intraoperative Radiotherapy for Patients with Carcinoma of the Pancreas , 2005, Pancreatology.

[14]  F. Motoi,et al.  Pancreatic Cancer Registry in Japan: 20 Years of Experience , 2004, Pancreas.

[15]  K. Campbell,et al.  Pancreaticoduodenectomy With or Without Distal Gastrectomy and Extended Retroperitoneal Lymphadenectomy for Periampullary Adenocarcinoma, Part 2: Randomized Controlled Trial Evaluating Survival, Morbidity, and Mortality , 2002, Annals of surgery.

[16]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[17]  T. Eberlein.  Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial , 2008 .

[18]  K. Campbell,et al.  Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: A prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors , 2003, Journal of Gastrointestinal Surgery.

[19]  M. Ikeda,et al.  Prognosis of advanced pancreatic cancer patients with reference to calorie intake. , 1998, Nutrition and cancer.